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Abstract
A third of patients receiving Interferon-α (IFN-α) treatment for Hepatitis-C develop major depressive disorder (MDD).
Conversely, anti-Tumor Necrosis Factor (TNF) therapies improve depression providing key empirical support for the
“inflammatory theory” of depression. Heightened amygdala reactivity (particularly to negatively valanced stimuli) is a
consistent finding within MDD; can predict treatment efficacy and reverses following successful treatment. However,
whether IFN-α and anti-TNF enhance/attenuate depressive symptoms through modulation of amygdala emotional reactivity
is unknown. Utilizing a prospective study design, we recruited 30 patients (mean 48.0 ± 10.5 years, 21 male) initiating IFN-α
treatment for Hepatitis-C and 30 (mean 50.4 ± 15.7 years, 10 male) anti-TNF therapy for inflammatory arthritis. All
completed an emotional face-processing task during fMRI and blood sampling before and after their first IFN-α (4-h) or anti-
TNF (24-h) injection and follow-up psychiatric assessments for 3 months of treatment. IFN-α significantly increased
depression symptoms (Hamilton Depression Rating Scale HAM-D) at 4 weeks (p < 0.001) but not 4-h after first dose (p >
0.1). Conversely, anti-TNF significantly improved depressive symptoms (Hospital Anxiety and Depression Rating Scale
HADS) at both 24-h (P= 0.015) and 12 weeks (p= 0.018). In support of our a-priori hypothesis, both IFN-α and anti-TNF
significantly modulated amygdala reactivity with IFN-α acutely enhancing right amygdala responses to sad (compared with
neutral) faces (p= 0.032) and anti-TNF conversely decreasing right amygdala reactivity (across emotional valence) (p=
0.033). Furthermore, these changes predicted IFN-induced increases in HAM-D 4 weeks later (R2= 0.17, p= 0.022) and
anti-TNF-associated decreases in HADS at 24-h (R2= 0.23, p= 0.01) suggesting that actions of systemic inflammation on
amygdala emotional reactivity play a mechanistic role in inflammation-associated depressive symptoms.
Introduction
Inflammation is increasingly implicated in the etiology of
depression [1]. Patients with major depressive disorder
(MDD) show activated inflammatory pathways including
raised pro-inflammatory cytokines [2], acute phase proteins
[3], chemokines, and adhesion molecules [4] in blood as
well as increased pro-inflammatory cytokines in cere-
brospinal fluid (CSF) [5, 6]. Conversely, patients with pro-
inflammatory diseases such as rheumatoid arthritis experi-
ence a high burden of depressive symptoms, that improves
following suppression of peripheral inflammation with
cytokine blockers such as the anti-Tumor Necrosis Factor
(anti-TNF) therapies [7]. Experimentally induced inflam-
mation can also acutely impair mood and induce anhedonia,
effects that have been linked to changes in amygdala,
subgenual cingulate, and striatal reactivity to emotional or
hedonically valanced stimuli [8–10]. A similar pattern of
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neuroimaging changes is also observed in MDD [11, 12],
suggesting that actions of inflammation on the neural pro-
cessing of emotionally valanced stimuli may, if prolonged,
predispose to the later development of depression.
Studies of patients treated with prolonged courses of pro-
inflammatory cytokines e.g., interferon-alpha (IFN-α) pro-
vide arguably the most compelling data for an etiological
role for inflammation in depression. When used to treat
hepatitis-C or malignant melanoma, a third of patients
develop major depression, typically within 4–8 weeks of
treatment onset [13, 14]. They also provide important
mechanistic insights into how actions of systemic inflam-
mation on the brain may precipitate depression. For exam-
ple, acute (3-h) cortisol and adrenocorticotrophic hormone
(ACTH) responses to IFN-α predict the subsequent devel-
opment of depression implicating the brain’s stress circuitry
[15]. Chronic IFN-α also induces the enzyme indoleamine-
2,3-dioxygenase to reduce serotonin synthesis and increase
metabolically active tryptophan metabolites such as
kynurenine [16, 17] and induces circumscribed increases in
striatal glucose uptake [18], glutamate concentration [19],
and dopamine turnover [20]. However, though cross-sec-
tional, and even a recent prospective study, have repeatedly
associated these striatal changes with impairments in
motivation and subjective fatigue [21], none has identified a
clear association with emergence of depressive symptoms
suggesting an alternate neurobiological substrate for these
effects.
In contrast, numerous studies have now demonstrated
anti-depressant properties of anti-cytokine therapies when
used in the context of chronic inflammatory disorders (e.g.,
inflammatory arthritis) [7, 22] or MDD with raised per-
ipheral inflammatory markers [23]. Preclinical investiga-
tions of their mechanistic actions are more limited, though
support clinical observations of a rapid (within 24 h) action
of anti-TNF therapies on the brain, including importantly,
inhibition of amygdala reactivity to emotionally salient
(pain) stimuli [24]. This later finding is notable as it high-
lights a key component of the brain stress-circuitry and
complements human studies in MDD where heightened
amygdala reactivity to emotionally salient stimuli is a
characteristic feature [11, 25]. Furthermore, in MDD,
heightened amygdala reactivity has been shown to be highly
dynamic, resolving rapidly on successful depression treat-
ment [25] and providing value in predicting therapeutic
success [26]. This has led to the proposal that amygdala
emotional reactivity may provide the neurobiological sub-
strate for the mood congruent processing bias integral to
this disorder [26].
Interestingly, this dynamic nature of amygdala reactivity
may underscore why the neural substrates for IFN-α
induced depression have remained obscure. To date, studies
of IFN-α-induced depression have focused on techniques
such as Fluorodeoxyglucose (FDG)-PET that are highly
sensitive to resting metabolic activity but not neural reac-
tivity. Consequently, actions on reactivity of neural circuits
implicated in emotional processing would go un-detected
and only become evident using task-based techniques such
as fMRI. In support of this, mild inflammatory challenges
increase the emotional reactivity [8] but not resting meta-
bolic activity (FDG-PET) [27] of brain regions sub-serving
emotional processing including amygdala and subgenual
cingulate [8]. Furthermore, though MDD patients typically
display heightened reactivity to emotionally valanced sti-
muli within brain regions sub-serving emotional processing
(particularly amygdala) [11, 25] they rarely demonstrate a
corresponding change in resting metabolic activity [28].
To address whether acute changes in amygdala emo-
tional reactivity induced by IFN-α/anti-TNF therapies pre-
dispose to the later development/resolution of depressive
symptoms we recruited 30 patients scheduled to start IFN-α
based therapy for chronic hepatitis-C infection and 30
patients scheduled to start anti-TNF based therapy for
inflammatory arthritis. All completed an emotional-face
processing task known to reliably engage affective brain
systems during fMRI on two separate sessions: 1 week
before treatment initiation and 4/24 h after their first dose of
IFN-α/anti-TNF therapy respectively. All were then fol-
lowed up for 3 months. We hypothesized that IFN-α would
acutely increase, and anti-TNF acutely decrease amygdala
reactivity to emotionally valanced faces. Furthermore, we
predicted that if acute changes in emotional reactivity pre-
dispose to emergence/resolution of depressive symptoms
induced by IFN-α/anti-TNF treatments respectively, these
changes should also predict subsequent changes in depres-
sive symptoms.
Materials and methods
Participants
Thirty individuals (21 male, mean 48.0 ± 10.5 years) were
recruited before initiating IFN-α-based therapy for
Hepatitis-C and 30 (10 male, mean 50.4 ± 15.7 years)
before initiating anti-TNF therapy for inflammatory arthritis
(25 Rheumatoid arthritis, 2 Psoriatic Arthritis, 3 Ankylosing
spondylitis). All were fluent in English, aged 18–69 years
and fulfilled National Institute for Health and Care Excel-
lence (NICE) guidelines for starting IFN-α-based therapy or
anti-TNF therapy. Participants had a baseline psychiatric
evaluation of current mental state and previous psychiatric
history, using the Mini Neuropsychiatric Inventory.
Hepatitis-C participants were excluded if they were
receiving treatment for depression at study enrollment, had
a history of psychotic or autoimmune illness, substance
K. A. Davies et al.
misuse in the last 6 months, were co-infected with human
immunodeficiency virus, or had any cause for liver disease
other than hepatitis C. Inflammatory arthritis patients were
excluded if they had co-morbid systemic lupus erythema-
tosus, untreated thyroid disease, stroke or multiple sclerosis,
or were receiving treatment for depression at study enroll-
ment. The study was approved by Cambridge Central (12/
EE/0491) and South East Coast (11/LO/1320) National
Research Ethics Committees. All subjects provided written
informed consent.
Study design
The study utilized a prospective cohort design. Participants
underwent an emotional face processing task during fMRI,
blood draw and behavioral testing at baseline (median
8 days before treatment) and after their first IFN-α (4 h) or
anti-TNF (24 h) injection timed to coincide with reported
onset of subjective symptoms (but not depressive symptoms
per-se) and preclinical data confirming actions of IFN-α and
anti-TNF on the brain at these timepoints [15, 21, 24, 29].
Inflammatory response and depressive symptoms were
evaluated at each fMRI visit and after 12 weeks of therapy
in all participants. IFN-α treated patients underwent addi-
tional behavioral assessments at 4 and 8 weeks to capture
the more rapid symptom evolution in this group. Consistent
with previous studies, profile of mood states (POMS),
Hamilton Depression Rating Scale (HAM-D), state and trait
anxiety inventory (STAI) and fatigue visual analog scale
(fVAS) were used to index changes in mood, depression/
anxiety and fatigue respectively in the IFN-α treated group.
Arthritis patients underwent a broader assessment designed
to capture additional changes in disease activity and pain.
This included: POMS, Hospital Anxiety and Depression
Scale (HADS), pain and fatigue VAS (pVAS, fVAS), Beck
Depression Inventory (BDI), and DAS28, Bath Ankylosing
Spondylitis Functional Index and Bath Ankylosing Spon-
dylitis Disease Activity Index or Psoriasis Area and
Severity Index and Psoriatic Arthritis Response Criteria as
appropriate. They were also given the option to return for a
third scanning session at 12 weeks to assess whether any
acute changes in emotional reactivity were sustained after
3 months of treatment (24 completed this additional
session).
Emotional face processing task
During each scanning session participants viewed 37
unique positive (happy), 37 negative (sad), and 37 neu-
trally valanced face stimuli, presented in random order.
Each stimulus was displayed for 3 s with a jittered 7-s
inter-trial interval. During stimulus display participants
were instructed to introspect on how the displayed
emotional facial expression reflected their current emo-
tional state. They indicated their response using a button
press (not at all/somewhat/quite a lot) immediately after
image offset. Two sets of face stimuli were used, coun-
terbalanced across the two imaging sessions. All partici-
pants were briefed on the task prior to scanning and all
completed the task well.
fMRI
T2*-weighted echo planar images (EPIs) were acquired on a
1.5 T Siemens Avanto scanner, equipped with a 32-channel
phased-array receive-only head coil using a −30° tilted
acquisition to reduce orbitofrontal dropout. Each volume
provided whole brain coverage (34 interleaved ascending
3 mm slices, 0.6 mm inter-slice gap, echo-time 34 ms: TR
2.52 s). High-resolution T1-weighted anatomical scan was
acquired using a magnetization-prepared-rapid-acquisition-
gradient-echo sequence to aid group level anatomical
localization. EPIs were analyzed in an event related manner
using SPM12. Preprocessing consisted of spatial realign-
ment, segmentation, and normalization of the mean EPI
image to a standard template then 8 mm3 spatial smoothing.
The ARTifact Detection Toolbox (http://cibsr.stanford.edu/
tools/human-brain-project/artrepair-software.html) [30] was
used to identify motion outliers, which were then inter-
polated in the general linear model. Subject-specific rea-
lignment parameters were modeled as covariates of no
interest.
We defined left and right amygdala as our primary a
priori ROIs based on the prior literature in idiopathic MDD
[25, 26], inflammation-associated mood change [8] and
depression [31] and preclinical use of anti-TNF [24]. Left
and right subgenual cingulate were included as additional
ROIs given their reported role in idiopathic depression
[32, 33] and inflammation-associated mood change [8].
Masks were produced using the WFU Pickatlas (http://fmri.
wfubmc.edu/software/pickatlas).
Stimulus onsets were modeled as 3s events and con-
volved with a canonical hemodynamic response function.
Linear contrasts of regression coefficients were computed at
the individual subject level then taken to group level flex-
ible factorial ANOVA or t-tests as appropriate. Main effects
of viewing emotional faces (happy, sad, neutral compared
with implicit baseline) were first tested in each group using
paired-sample t-tests. Effects of IFN-α and anti-TNF on the
processing of all emotional faces (happy, sad, and neutral)
and on sad compared with neutral expressions were then
tested in flexible factorial ANOVAs (factors: drug (IFN,
anti-TNF), time (pre, post drug).
Finally, we performed a regression analysis to investigate
whether acute actions of pro (IFN-α) or anti-inflammatory
challenges (anti-TNF) on the neural processing of
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emotionally valanced stimuli predicted the later develop-
ment/attenuation of depressive symptoms. To minimize
variance induced by change in medication (e.g., starting an
antidepressant), we restricted this analysis to the next
assessment i.e., change in depressive symptoms at 4 weeks
in IFN-α group and 12 weeks in the arthritis group. Spe-
cifically, we investigated whether acute changes in neural
reactivity to sad compared with neutral stimuli or to all
emotional expressions within amygdala or subgenual cin-
gulate ROIs predicted the subsequent development of
depression symptoms.
Multiple comparisons
Whole-brain corrected cluster significance was determined
using robust Family Wise Error (FWE) correction. Only
clusters surviving whole brain or ROI small-volume FWE
correction α < 0.05 after thresholding at an uncorrected
statistical threshold of p < 0.001 are reported.
Behavioral analyses
The primary outcome variable was change in depressive
symptoms (HAM-D at 4 weeks in the in the IFN-α group
and HADSd at 12 weeks in the anti-TNF group). Data are
also reported for changes in each of the other measures.
Effects of IFN-α/anti-TNF on depressive symptoms and
cytokines were analyzed in SPSS 22.0 using repeated
measures ANOVAs and subsequent paired sample t-tests.
Mauchly’s test of sphericity was performed, and results
reported followed Greenhouse-Geisser correction where
appropriate. Change in arthritis disease activity is reported
for the rheumatoid arthritis patients using the DAS28-CRP
= 0.56 × √(TEN28)+ 0.28 × √(SW28)+ 0.36 × ln(CRP+
1) + 0.014 × GH+ 0.96. Where TEN= Tender joint count,
SW= Swollen joint count and GH= Patient Global Health
assessment from 0 (best) to 100 (worst).
Cytokine analyses
Blood (20 mL) was drawn into Vacutainer tubes containing
ethylenediaminetetraacetic acid (EDTA) anticoagulant,
centrifuged at 1300 rpm for 10 min and plasma was
removed, aliquoted, and frozen at −80 °C before analysis.
Plasma IFN-α was measured using high sensitivity Ver-
iKineTM ELISA (human IFN-α multi-subtype kit, PBL
Assay Science, Piscataway, USA). Interleukin-6 (IL-6),
Tumor Necrosis factor (TNF), IL-1β and IL-10 using high
sensitivity Quantikine® ELISAs (R&D Systems, Abingdon,
UK) and IL-1 Receptor antagonist (IL-1Ra) using Quanti-
kine® ELISA. Cytokines were selected based on the pre-
vailing literature to provide an index of both pro- and anti-
inflammatory responses.
Results
Cytokine response
As anticipated, IFN-α was associated with a significant
increase in plasma IFN-α (from mean (± s.e.) 3.12 ±
0.95 pmol/L at baseline to 43.26 ± 7.66 pmol/L at 4 h, t
(29)= 5.12, p < 0.001). Plasma TNF was not significantly
altered at this time point (2.51 ± 0.37 to 2.95 ± 0.48 pmol/L,
t(29)=−0.85, p= 0.40. However, we did observe an
approximately threefold increase in IL-6 (1.85 ± 0.35 to
4.98 ± 0.69 pmol/L, t(29)=4.41, p < 0.001) as well as sig-
nificant increases in IL-1 receptor antagonist (IL-1ra) from
191.57 ± 28.52 to 592.20 ± 113.12 pmol/L (t(29)=3.66, p=
0.001) and IL-10 from 0.85 ± 0.18 to 1.40 ± 0.25 pmol/L
(t(29)= 2.85, p= 0.008) demonstrating a broader pro and
anti-inflammatory cytokine response to IFN-α (Fig. 1).
Cytokine responses to anti-TNF (Fig. 2) broadly mir-
rored those to IFN-α with a halving of IL-6 at 24 h (6.41 ±
1.72 to 3.05 ± 0.97 pmol/L, t(27)=−2.55, p= 0.017) as
well as significant reductions in IL-1ra and IL-10 (766.33 ±
249.22 to 490.74 ± 195.21 pmol/L, t(27)=−2.06, p= 0.049
and 0.30 ± 0.13 to 0.22 ± 0.12 pmol/L, t(27)=−2.53, p=
0.017) respectively. TNF concentrations showed a non-
significant increase at this time point likely reflecting
increased circulating bound TNF (0.94 ± 0.45 to 3.19 ±
1.42 pmol/L, t(27)= 1.47, p= 0.15).
Depression symptoms
IFN-α significantly increased depressive symptoms
(HAM-D: F(4,116)=29.72, p < 0.001) rising from 7.00 ±
1.32 at baseline to peak 16.90 ± 1.75 at 8 weeks, with
significant effects observed from 4 weeks until the end of
treatment. However, we observed no significant increase in
depression symptoms (HAM-D) immediately after IFN-α
(7.00 ± 1.32 to 7.50 ± 1.42, t(29)= 0.89, p= 0.38), nor any
association between acute changes in depression (4 h) and
subsequent development of depression symptoms at 4, 8,
or 12 weeks.
Conversely, anti-TNF significantly reduced depressive
symptoms (HADSd) (F(2,56)= 4.81, p= 0.012) from 6.31 ±
3.07 at baseline to trough 4.82 ± 3.34 at 12 weeks with
significant effects observed at both 24 h (t(28)= 2.60, p=
0.015) and 12 weeks (t(28)= 2.51, p= 0.018). Similar
effects were also observed in cognitive symptoms of
depression measured with the BDI (24 h (t(28)= 3.25, p=
0.003), 12 weeks (t(28)= 3.78, p= 0.001). HADS anxiety
subscale showed a trend toward a reduction in anxiety
(24 h: t(28)= 1.94, p= 0.063; 12 weeks: t(28)= 3.25, p=
0.053) (Fig. 2). Interestingly, improvement in depressive
symptoms at 24 h was not associated with a significant
change in joint pain (pVAS t(28)= 0.96, p= 0.347).
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However, there was a significant improvement in the
composite measure of disease activity (DAS28-CRP) that
includes a subjective rating of global health at this time-
point (t(28)= 2.92, p= 0.007). Clinical and demographic
data are summarized in Table 1.
Processing of emotionally valanced stimuli
Emotional face stimuli (happy, sad, neutral) in both IFN-α
and anti-TNF groups robustly activated the matrix of neural
structures encompassing occipital visual cortices, bilateral
fusiform face area and bilateral amygdala identified in
previous meta-analysis [34] (Fig. 3a, d); and evoked strong
activations in bilateral dorsal anterior cingulate and superior
parietal lobule and left primary motor cortex confirming
task engagement (SI Tables 1 and 2).
We observed no significant main effect of IFN-α
(viewing all emotional face stimuli at 4 h > baseline)
(Table 2). However in line with our hypothesis, the inter-
action between IFN-α and processing of negative (sad)
compared with neutrally valanced stimuli demonstrated a
significant effect within the right amygdala ([18,−6,−28],
Z= 4.19, FWE small volume correction p= 0.032), with
sad (compared with neutral) faces inducing a significantly
greater right amygdala response 4 h after IFN-α compared
with baseline (Fig. 3b, Table 2). Significant interactions
were also observed at the whole brain level in bilateral
visual cortices and right fusiform face areas confirming a
broader impact of IFN-α on negatively valanced emotional
processing. Conversely, anti-TNF was associated with a
significant decrease in right (and left) amygdala reactivity
that was observed across all emotional expressions (main
effect of IFN) but not significantly different for sad com-
pared with neutral expressions (i.e., no interaction) (Fig. 3e,
Table 2). See SI Tables 3–6 for additional results and results
at 3 months.
To explore how these acute IFN-α/anti-TNF-induced
changes in amygdala reactivity contribute to the emer-
gence/resolution of depressive symptoms, we next inves-
tigated whether they predicted changes in depressive
symptoms at 4/12 weeks, respectively. This regression
analysis demonstrated that IFN-α induced changes in
amygdala reactivity (sad compared with neutral stimuli)
significantly predicted the subsequent development of
depressive symptoms at 4 weeks (HAM-D, F(1,29)= 5.84,
adjusted R2= 0.17, p= 0.022). Specifically, patients
Fig. 1 Mood and cytokine responses to interferon-alpha. Violin
plot illustrating data distributions (probability density), median and
interquartile ranges. a Hamilton Depression Rating Scale (HAM-D)
and State Anxiety (STAI) at baseline, 4 h, 4, 8, and 12 weeks after
starting IFN-α based therapy. P values relate to comparison with
baseline values. b Log plasma Interleukin (IL)-6, Tumor Necrosis
factor (TNF), IL1 receptor antagonist (IL1ra) and IL-10 concentration
at baseline and 4 h after the first injection of IFN-α.
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showing the greatest increase in neural reactivity to sad
facial expressions after the first dose of IFN-α subse-
quently showed the greatest increase in HAM-D depressive
symptoms (Fig. 3c). Conversely anti-TNF induced changes
in amygdala reactivity at 24 h (across emotional expres-
sions) significantly correlated with co-incident changes in
depressive symptoms (HADSd, F(1,28)= 7.81, adjusted R2
= 0.23, p= 0.01) but not changes in depressive symptoms
12 weeks later (p > 0.1) (Fig. 3f). Of note, this significant
anti-TNF induced reduction in amygdala reactivity was
sustained at 12 weeks (SI Table 3). At this later timepoint,
the correlation with coincident change in depressive
symptoms persisted, but more weakly and only at trend
level in this smaller group (HADSd, F(1,23)=2.94, adjusted
R2= 0.12, p= 0.10). Results reported were not sig-
nificantly influenced by sex differences (see SI Results, SI
Table 7 and SI Fig. 1).
Discussion
Here we show that pro- and anti-inflammatory therapies
differentially reorient amygdala emotional reactivity. This
bidirectional reorientation in amygdala reactivity occurred
rapidly (within 4 h of IFN-α injection and 24 h of anti-TNF)
and scaled with changes in depressive symptoms. Follow-
ing IFN-α, this was observed as a selective increase in right
amygdala responsivity to negative (sad) versus neutrally
valanced expressions and occurred prior to any change in
depressive symptoms. Furthermore, it predicted the sub-
sequent development of depressive symptoms, explaining
~17% of the increase in HAM-D symptoms 4 weeks later.
In contrast, anti-TNF therapy acutely decreased amygdala
reactivity across the range of emotional expressions (happy,
sad and neutral) with no evidence of any selective effect on
sad versus neutral expressions. Again, this change in
Fig. 2 Mood and cytokine responses to anti-TNF therapy. Violin
plot illustrating data distributions (probability density), median and
interquartile ranges. a Hospital Anxiety and Depression Rating Scale
(HADS) total and depression (HADSd) and anxiety (HADSa) sub-
scales at baseline, 24 h and 12 weeks after starting anti-TNF therapy.
b Log plasma Interleukin (IL)-6, Tumor Necrosis factor (TNF) and IL1
receptor antagonist (IL1ra) at baseline, 24 h and 12 weeks after starting
anti-TNF therapy. c Becks Depression Inventory (BDI), visual analog
scale for pain (pVAS) and composite disease activity score (DAS28
CRP) at baseline, 24 h and 12 weeks after starting anti-TNF therapy.
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amygdala reactivity scaled with changes in depressive
symptoms (improvement). However, in this group changes
in depressive symptoms occurred early (within 24 h) and
co-occurred with changes in amygdala reactivity, confirm-
ing the association between coincident changes in amygdala
reactivity and depressive symptoms but did not provide
additional predictive power for further change in depressive
symptoms 12 weeks later. Together, these findings extend
evidence from experimentally-induced inflammation that
link changes in amygdala, subgenual cingulate and striatal
emotional reactivity to acute changes in mood [8, 9]. By
demonstrating that selective changes in amygdala function
precede the development of depressive symptoms our
findings have relevance beyond IFN-α treatment to suggest
a cytokine-mediated mechanism through which sustained
systemic inflammation may also predispose to the devel-
opment of depression.
Within depression, heightened amygdala reactivity to
negatively valanced emotional stimuli (sad faces and words)
is a reliable finding [25, 28] and has been proposed to
mediate the characteristic mood-congruent processing bias
[35]. It has value in predicting therapeutic response to CBT
[26], normalizes following successful treatment with selective
serotonin reuptake inhibitors [35] and in patients in remission
serves as a physiological vulnerability marker for relapse
[35]. However, the amygdala is also critical to the initiation
and integration of broader stress responses [36]. This includes
a central role in integrating behavioral and hypothalamic–
pituitary–adrenal endocrine responses to extrinsic (e.g., psy-
chological) stressors [36] but also modulation of cortisol
stress responses to intrinsic stressors including systemic
cytokine challenge [37]. This later finding is noteworthy
given earlier evidence that acute ACTH and cortisol
responses to Interferon can also predict the later emergence of
depressive symptoms [15] and provides a potential mechan-
istic link between these and our current data.
How IFN-α and anti-TNF act on the brain to alter
amygdala reactivity and why they show differential speci-
ficity (Increased sensitivity to sad versus neutral expres-
sions, versus decreased sensitivity to all emotional stimuli,
Table 1 Demographics of the
Hepatitis-C and Inflammatory
Arthritis Groups.
Arthritis
(Baseline)
Arthritis (12-
Wks)
p value Hep-C
(Baseline)
Hep-C (4-
Wks)
p value
Age (years) 50.4 ± 15.7 48.0 ± 10.5 0.39
Sex
Male 10 21 0.005
Female 20 9
Depression Scorea 6.3 ± 3.1 4.8 ± 3.3 0.018 7.0 ± 7.1 15.6 ± 8.0 <0.001
F-VAS 66.3 ± 20.5 42.0 ± 24.8 <0.001 34.8 ± 26.9 63.4 ±
29.0
<0.001
Additional assessments in the Inflammatory Arthritis group
P-VAS 57.7 ± 23.5 39.8 ± 27.5 0.001 – – –
BDI 14.4 ± 8.1 9.4 ± 8.2 0.001 – – –
DAS28-CRP 5.7 ± 1.1 4.3 ± 1.5 <0.001 – – –
Additional details for the Inflammatory Arthritis group
Diagnosis
Rheumatoid
Arthritis (RA)
25
Psoriatic
Arthritis (PsA)
2
Ankylosing
Spondylitis (AS)
3
Treatment
Adalimumab 13 (11
RA, 2 PsA)
Certolizumab 10 (10 RA)
Etanercept 5 (3 RA, 2 AS)
Golimumab 2 (1 RA, 1 AS)
Data represent mean ± standard deviation. F-VAS and P-VAS fatigue- and pain- Visual Analog Scale scores
(0–100) respectively; BDI: Beck’s Depression Inventory; DAS28-CRP (28 Item Disease Activity Score).
aValues denote HADSd Hospital Anxiety and Depression Rating Scale (Depression component) for
Inflammatory Arthritis and HAM-D Hamilton Depression Rating Scale for Hepatitis-C patients.
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respectively) remains incompletely understood, though may
be usefully informed by the rodent and non-human primate
literature. Firstly, both IFN-α and TNF have been shown to
cross the rodent blood-brain barrier (BBB) [38]. Three-fold
increases in CSF IFN-α have also been reported from 3 h of
systemic IFN-α injection in rhesus monkeys [39] and
similar elevations in CSF IFN-α observed after 12 weeks of
IFN-α therapy in humans [17]. Further, in rodents, intra-
peritoneal injection of even modest amounts of IFN-α
rapidly induces IFN-sensitive genes within the brain
[40, 41] and increases neuronal firing rates within amygdala
and other brain regions [29]. Within the hypothalamus,
IFN-α can differentially modulate neuronal firing rates in
lateral (hunger) and ventro-medial (satiety) related nuclei
[29]. Whether, the selective effects of IFN-α on negatively
valanced information relates to similar differential effects
within the amygdala remains to be determined.
In contrast, raised pro-inflammatory cytokines (particu-
larly TNF and IL-1β) have been reported in CSF in humans
and rodent models of Inflammatory Arthritis [42] with
recent CSF proteomic analysis showing that anti-TNF ther-
apy reduces CSF concentrations of a range of acute
phase and immune response proteins [43]. Interestingly, TNF
has also been shown to mediate homeostatic synaptic scal-
ing, the mechanism used by the brain to allow individual
neurons to modulate their overall action potential firing rate
in response to chronically elevated/reduced activity within
their neural circuit [44]. More specifically, TNF increases
neuronal post-synaptic AMPA receptor expression resulting
in a uniform increase to the strength of ALL synapses to the
cell. Theoretically, this mechanism may underlie why we
observed a global reduction in amygdala reactivity (across
emotional expressions) following anti-TNF therapy.
Use of two complimentary patient groups initiating pro-
(IFN-α) and anti- (anti-TNF) inflammatory therapies is a
major strength of our study that enabled us to demonstrate
that systemic inflammation can rapidly and bidirectionally
reorient amygdala reactivity to emotionally valanced
Fig. 3 Effects of interferon-alpha and anti-TNF on brain emotional
reactivity. Top row Hepatitis-C patients initiating interferon-alpha
(IFN). Bottom row inflammatory arthritis patients initiating anti-TNF
(aTNF) a+ d Main effect of viewing emotional (sad, happy, neutral)
faces versus implicit baseline pre and post IFN and aTNF, respec-
tively. Amygdala responses are indicated with red circles. b Increase
in right amygdala reactivity to sad versus neutral stimuli 4 h after IFN
compared with baseline (pre-IFN). Inset shows mean contrast estimate
for sad > neutral contrast for the right amygdala ROI at baseline and
4 h after IFN. c Correlation between acute change in right Amygdala
reactivity to Sad versus neutral face stimuli (4 h minus baseline) and
subsequent change in HAM-D score (4 weeks minus baseline).
e Decrease in right amygdala reactivity to ALL emotional stimuli 24 h
after IFN compared with baseline (pre-aTNF). Inset shows mean
contrast estimate for happy (H), sad (S) and neutral (N) facial
expressions for the right amygdala ROI at baseline and 24 h after anti-
TNF f Correlation between change in right Amygdala reactivity to
ALL emotional stimuli (24 h after aTNF minus baseline) and coin-
cident change in HADS depression (HADSd) score (24 h minus
baseline). Color scale bars denote Z score.
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stimuli. Further, by following these patients up over time
we were able to demonstrate that these acute bi-directional
actions on this key component of the brain stress response
circuitry scaled with development/resolution of depressive
symptoms. However, our use of clinical groups also had a
number of inherent weaknesses: For example, we did not
enrich the arthritis group for depression at baseline, which
may underlie why we observed only a modest reduction in
HADSd (~1.5 points or 24%) following anti-TNF. Further,
for clinical scheduling reasons we needed to complete this
study in a clinical (1.5 T) MRI scanner and to follow up this
group at 12 (rather than 4) weeks which may underlie why
acute changes in amygdala reactivity predicted only con-
current (but not future) change in depressive symptoms in
this group. Nevertheless, our current study extends prior
studies implicating acute stress responses in IFN-α-induced
depression [15] and provides a potential brain mechanism
through which bidirectional changes in peripheral inflam-
mation contribute to the development/resolution of depres-
sive symptoms.
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